Morgan Stanley analyst Patrick Wood raised the firm’s price target on Sight Sciences (SGHT) to $8 from $6 and keeps an Equal Weight rating on the shares. Going into 2026, MedTech “looks well-positioned on several fronts” as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for “a solid industry setup,” the analyst tells investors in a note for the group on the upcoming year.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- VTI ETF Daily Snapshot—12/01/2025
- Sight Sciences announces results from three manuscripts on treating glaucoma
- Sight Sciences’ Earnings Call: Mixed Sentiment and Strategic Advances
- Sight Sciences price target raised to $5 from $4 at Piper Sandler
- Balanced Outlook: Hold Rating on Sight Sciences Amid Strong Performance and Uncertainties